Renal Cancer - Results from #2120

Application of diffusion kurtosis tensor MR imaging in characterization of renal cell carcinomas with different pathological types and grades. March 25, 2021

Safety and oncological outcome following radiofrequency ablation of small renal masses in a single center. March 24, 2021

Outcomes of patients with intermediate- or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. March 24, 2021

Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies. March 23, 2021

What is next in second- and later-line treatment of metastatic renal cell carcinoma? review of the recent literature. March 23, 2021

Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. March 22, 2021

Dual immune check point blockade or immune check point-tyrosine kinase inhibitor combination: as a first-line treatment in metastatic renal cell carcinoma? March 22, 2021

Renal cell carcinoma pathology in 2021: 'new need for renal cancer immune profiling'. March 22, 2021

New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia. March 19, 2021

The efficacy and safety of the combination of axitinib and pembrolizumab-activated autologous DC-CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study. March 19, 2021

Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry. March 18, 2021

Development of a histopathology informatics pipeline for classification and prediction of clinical outcome in subtypes of renal cell carcinoma. March 18, 2021

Prognostic effect of preoperative serum albumin to globulin ratio in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. March 17, 2021

Computed Tomography-Based Radiomics Model for Predicting the WHO/ISUP Grade of Clear Cell Renal Cell Carcinoma Preoperatively: A Multicenter Study. March 17, 2021

FDA Grants Priority Review for New Drug Application for HIF-2α Inhibitor Belzutifan (MK-6482) March 16, 2021

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. March 16, 2021

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Final results of cohorts A, G, H, and I of IVY Phase I study. March 16, 2021

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. March 15, 2021

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. March 15, 2021

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. March 12, 2021

Page 107 of 456